Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890180 | 0.86 | AKR1C1 (0.57) | MEN1KMT2AAKR1C1OPRD1CA12 | |
| SCHEMBL631791 | 0.85 | AKR1C1 (0.68) | MEN1KMT2ACYP2C9AKR1C1HDAC4 | |
| SCHEMBL3737199 | 0.82 | AKR1C1 (0.70) | MEN1KMT2AAKR1C1OPRD1CA12 | |
| SCHEMBL15215650 | 0.82 | AKR1C1 (0.48) | MEN1KMT2ACYP2C9AKR1C1OPRD1 | |
| SCHEMBL12928712 | 0.82 | AKR1C1 (0.64) | MEN1KMT2AAKR1C1OPRD1CA12 | |
| SCHEMBL11287102 | 0.82 | HSD11B1 (0.40) | MEN1KMT2ACYP2C9HSD11B1OPRM1 | |
| SCHEMBL19358562 | 0.82 | HSD11B1 (0.40) | MEN1KMT2ACYP2C9OPRD1CA12 | |
| SCHEMBL8747873 | 0.82 | HDAC4 (0.52) | MEN1KMT2ACYP2C9OPRD1HDAC4 | |
| Ethylene SCHEMBL3968000 | 0.81 | AKR1C1 (0.63) | MEN1KMT2ACYP2C9AKR1C1HDAC4 | |
| SCHEMBL1838291 | 0.81 | AKR1C1 (0.68) | MEN1KMT2AAKR1C1HDAC4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2017161145-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161145-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20130225615-A1 | 2-CYCLOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2011035355-A1 | NOVEL ANTIMALARIAL 3-AZABICYCLO[3.2.2]NONANE DERIVATIVES | UNIVERSITY OF GRAZ (AT) | 2011-03-31 | — | — | WO | disclosed |
| EP-2301627-A1 | Novel antimalarial 3-azabicyclo[3.2.2]nonane derivatives | University of Graz (AT) | 2011-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225615-A1 | 2-CYCLOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | JAK2, JAK3, TYK2 | MEN1 3028/4885KMT2A 688/4885CYP2C9 2004/4885 |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | EPX, MPO, SERPINB1 | MEN1 4785/4885KMT2A 3328/4885CYP2C9 391/4885 |
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | EPX, MPO, SERPINB1 | MEN1 4785/4885KMT2A 3328/4885CYP2C9 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.